Advertisement
Screener

IMMUNITYBIO, INC. (IBRX) Interest and Other Income

2.8 / 5 stars · 68/120 Roast Me

IMMUNITYBIO, INC. Interest and Other Income

IMMUNITYBIO, INC. (IBRX) reported Interest and Other Income of $736.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.

Financial Statements › Income Statement › Other Income

us-gaap:InterestAndOtherIncome · last filed 2026-05-07

  • IMMUNITYBIO, INC. interest and other income for the quarter ending 2026-03-31 was $736.00K, a 41.54% increase year-over-year.
  • IMMUNITYBIO, INC. interest and other income for the quarter ending 2025-12-31 was $579.00K, a 24.71% decline year-over-year.
  • IMMUNITYBIO, INC. interest and other income for the quarter ending 2025-09-30 was $772.00K, a 21.00% increase year-over-year.
  • IMMUNITYBIO, INC. interest and other income for the quarter ending 2025-06-30 was $818.00K, a 1.80% decline year-over-year.
  • IMMUNITYBIO, INC. interest and other income for fiscal 2025 was $2.69M, a 12.04% increase from fiscal 2024.
  • IMMUNITYBIO, INC. interest and other income for fiscal 2024 was $2.40M, a 178.10% increase from fiscal 2023.
  • IMMUNITYBIO, INC. interest and other income for fiscal 2023 was $863.00K, a 68.13% decline from fiscal 2022.
  • IMMUNITYBIO, INC. interest and other income for fiscal 2022 was $2.71M, a 223.92% increase from fiscal 2021.
Period endInterest and Other Income 3 monthInterest and Other Income 6 monthInterest and Other Income 9 monthInterest and Other Income 12 month
2026-03-31$736.00K
10-Q · filed 2026-05-07
$1.31M
derived: sum of 2 quarters · filed 2026-05-07
$2.09M
derived: sum of 3 quarters · filed 2026-05-07
$2.90M
derived: sum of 4 quarters · filed 2026-05-07
2025-12-31$579.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$1.35M
derived: sum of 2 quarters · filed 2026-02-23
$2.17M
derived: sum of 3 quarters · filed 2026-02-23
$2.69M
10-K · filed 2026-02-23
2025-09-30$772.00K
10-Q · filed 2025-11-05
$1.59M
derived: sum of 2 quarters · filed 2025-11-05
$2.11M
10-Q · filed 2025-11-05
$2.88M
derived: sum of 4 quarters · filed 2026-05-07
2025-06-30$818.00K
10-Q · filed 2025-08-05
$1.34M
10-Q · filed 2025-08-05
$2.11M
derived: sum of 3 quarters · filed 2026-05-07
$2.75M
derived: sum of 4 quarters · filed 2026-05-07
2025-03-31$520.00K
10-Q · filed 2026-05-07
$1.29M
derived: sum of 2 quarters · filed 2026-05-07
$1.93M
derived: sum of 3 quarters · filed 2026-05-07
$2.76M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$769.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$1.41M
derived: sum of 2 quarters · filed 2026-02-23
$2.24M
derived: sum of 3 quarters · filed 2026-02-23
$2.40M
10-K · filed 2026-02-23
2024-09-30$638.00K
10-Q · filed 2025-11-05
$1.47M
derived: sum of 2 quarters · filed 2025-11-05
$1.63M
10-Q · filed 2025-11-05
$1.01M
derived: sum of 4 quarters · filed 2026-02-23
2024-06-30$833.00K
10-Q · filed 2025-08-05
$993.00K
10-Q · filed 2025-08-05
$370.00K
derived: sum of 3 quarters · filed 2026-02-23
$980.00K
derived: sum of 4 quarters · filed 2026-02-23
2024-03-31$160.00K
10-Q · filed 2025-05-12
-$463.00K
derived: sum of 2 quarters · filed 2026-02-23
$147.00K
derived: sum of 3 quarters · filed 2026-02-23
$739.00K
derived: sum of 4 quarters · filed 2026-02-23
2023-12-31-$623.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$13.00K
derived: sum of 2 quarters · filed 2026-02-23
$579.00K
derived: sum of 3 quarters · filed 2026-02-23
$863.00K
10-K · filed 2026-02-23
2023-09-30$610.00K
10-Q · filed 2024-11-12
$1.20M
derived: sum of 2 quarters · filed 2024-11-12
$1.49M
10-Q · filed 2024-11-12
$2.00M
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30$592.00K
10-Q · filed 2024-08-12
$876.00K
10-Q · filed 2024-08-12
$1.39M
derived: sum of 3 quarters · filed 2025-03-03
$1.64M
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$284.00K
10-Q · filed 2024-05-09
$799.00K
derived: sum of 2 quarters · filed 2025-03-03
$1.05M
derived: sum of 3 quarters · filed 2025-03-03
$1.70M
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31$515.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$768.00K
derived: sum of 2 quarters · filed 2025-03-03
$1.41M
derived: sum of 3 quarters · filed 2025-03-03
$2.71M
10-K · filed 2025-03-03
2022-09-30$253.00K
10-Q · filed 2023-11-09
$897.00K
derived: sum of 2 quarters · filed 2023-11-09
$2.19M
10-Q · filed 2023-11-09
$2.48M
derived: sum of 4 quarters · filed 2024-03-19
2022-06-30$644.00K
10-Q · filed 2023-08-08
$1.94M
10-Q · filed 2023-08-08
$2.22M
derived: sum of 3 quarters · filed 2024-03-19
$2.33M
derived: sum of 4 quarters · filed 2024-03-19
2022-03-31$1.30M
10-Q · filed 2023-05-11
$1.58M
derived: sum of 2 quarters · filed 2024-03-19
$1.68M
derived: sum of 3 quarters · filed 2024-03-19
$1.79M
derived: sum of 4 quarters · filed 2024-03-19
2021-12-31$284.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19
$385.00K
derived: sum of 2 quarters · filed 2024-03-19
$497.00K
derived: sum of 3 quarters · filed 2024-03-19
$836.00K
10-K · filed 2024-03-19
2021-09-30$101.00K
10-Q · filed 2022-11-09
$213.00K
derived: sum of 2 quarters · filed 2022-11-09
$552.00K
10-Q · filed 2022-11-09
$1.08M
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$112.00K
10-Q · filed 2022-08-08
$451.00K
10-Q · filed 2022-08-08
$977.00K
derived: sum of 3 quarters · filed 2023-03-01
$1.51M
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$339.00K
10-Q · filed 2022-05-10
$865.00K
derived: sum of 2 quarters · filed 2023-03-01
$1.40M
derived: sum of 3 quarters · filed 2023-03-01
$1.74M
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$526.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$1.06M
derived: sum of 2 quarters · filed 2023-03-01
$1.40M
derived: sum of 3 quarters · filed 2023-03-01
$1.73M
10-K · filed 2023-03-01
2020-09-30$536.00K
10-Q · filed 2021-11-12
$877.00K
derived: sum of 2 quarters · filed 2021-11-12
$1.20M
10-Q · filed 2021-11-12
2020-06-30$341.00K
10-Q · filed 2021-08-12
$663.00K
10-Q · filed 2021-08-12
2019-12-31$2.76M
10-K · filed 2022-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
Immunovant, Inc. (IMVT)United States$7.028B-14.78
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CRISPR Therapeutics AG (CRSP)$5.390B-11.68